Abstract Details
|
Sarah E. Buerki, MD
(University Children'S Hospital Zurich)
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Marna McKenzie | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Cyrus Boelman, MD (BC Children'S Hospital) | No disclosure on file |
| No disclosure on file | |
| Clara Van Karnebeek | No disclosure on file |
| No disclosure on file | |
| Linda Huh, MD (British Columbia Children'S Hospital) | No disclosure on file |
| Anita Datta, MD (BC Childrens Hospital) | No disclosure on file |
| Kathy Selby, MD (U of BC Childrens Hospital) | The institution of Dr. Selby has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Selby has received research support from Biogen . The institution of Dr. Selby has received research support from Italfarmico. The institution of Dr. Selby has received research support from Reverogen. |
| Aspasia Michoulas, MD | No disclosure on file |
| Tanya Nelson, PharmD (Orhto-McNeil Neurologics) | No disclosure on file |
| Mary B. Connolly, MD (British Columbia'S Children'S Hospital) | Dr. Connolly has nothing to disclose. |
| Matthew Farrer, PhD (University of British Columbia) | No disclosure on file |
| Michelle Demos, MD (BC Children'S Hospital) | No disclosure on file |